Literature DB >> 7890907

Differential sensitivity of hepatitis C virus quasispecies to interferon-alpha therapy.

M Mizokami1, J Y Lau, K Suzuki, T Nakano, T Gojobori.   

Abstract

The quasispecies nature of hepatitis C virus was investigated in a patient with chronic hepatitis C virus infection who underwent interferon-alpha therapy. The hepatitis C virus E2/NS1 region was amplified and cloned, and multiple clones were sequenced before and after interferon-alpha therapy. The hepatitis C virus quasispecies can be grouped into three groups by phylogenetic tree analysis. Quasispecies from all the groups were present before interferon-alpha therapy. However, only group 3 remained after interferon-alpha therapy. In addition, only group 3 hepatitis C virus quasispecies were present during the early biochemical relapse. These data indicate that various groups of hepatitis C virus quasispecies may have different sensitivity to interferon-alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7890907     DOI: 10.1016/s0168-8278(94)80254-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

Review 1.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 3.  [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].

Authors:  A Ambrosch; W König
Journal:  Med Klin (Munich)       Date:  1999-11-15

4.  Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

Authors:  S J Polyak; S McArdle; S L Liu; D G Sullivan; M Chung; W T Hofgärtner; R L Carithers; B J McMahon; J I Mullins; L Corey; D R Gretch
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.